Hims & Hers removes a knock-off weight loss drug days after introducing it

Core Viewpoint - Hims & Hers launched a once-a-day weight-loss pill as a cheaper alternative to Novo Nordisk's Wegovy but decided to stop selling it shortly after due to industry feedback and regulatory scrutiny [1][2]. Company Actions - Hims & Hers initially claimed that the compounded semaglutide pill met "rigorous clinical standards" upon its launch [2]. - The company announced its decision to cease offering the treatment after engaging in discussions with industry stakeholders [2]. Regulatory Environment - The FDA issued a statement indicating its intention to restrict certain ingredients in non-FDA-approved compounded drugs, specifically targeting companies like Hims & Hers [8]. - The FDA warned that failure to address violations related to unapproved compounded GLP-1 products could lead to legal actions, including seizure and injunction [8]. Industry Context - Novo Nordisk revitalized the weight-loss medication market with its Ozempic product in 2022, which was initially marketed for type 2 diabetes but later prescribed for obesity [9]. - Following the success of Ozempic, Novo Nordisk developed Wegovy, specifically for weight management, which included an oral version launched in January [9]. - The surge in demand for weight-loss medications has led many health-focused companies to create off-brand versions to capitalize on the market [10].